Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
XERS Stock Chart & Stats
$5.60
<$0.01(0.15%)
At close: 4:00 PM EST
$5.60
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$3.81 - $10.08
Previous CloseN/A
Volume530.95K
Average Volume (3M)1.95M
Market Cap
$941.47M
Enterprise Value$868.19M
Total Cash (Recent Filing)$111.04M
Total Debt (Recent Filing)$37.76M
Price to Earnings (P/E)2273.2
Beta1.35
Next Earnings
May 07, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding172,431,290
10 Day Avg. Volume2,418,091
30 Day Avg. Volume1,953,393
Financial Highlights & Ratios
PEG Ratio-22.52
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue2.97
Enterprise Value/Gross Profit3.64
Enterprise Value/Ebitda24.79
Forecast
1Y Price Target
$10.00Price Target Upside78.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.18
Revenue Forecast (FY)$368.00M
Bulls Say, Bears Say
Bulls Say
Core Product GrowthAnalyst identifies Recorlev as the core growth driver and anticipates continued rapid sales expansion that could outperform consensus and materially boost revenue prospects.
Patent/ANDA RiskAnalyst views the ANDA filing referencing Recorlev as a routine aspect of a successful drug lifecycle rather than evidence of patent vulnerability, reducing perceived near-term generic risk.
Profitability And MarginsAnalyst expects expanding gross margins and improving operating leverage to support sustained profitability and a self-sustaining balance sheet while funding commercial and pipeline investments.
Bears Say
Sustainability And Regulatory RiskAnalyst raises concern about whether the main drug's growth drivers can be sustained and warns that regulatory setbacks for a related product could weaken long-term revenue forecasts.
Visibility And Interim VolatilityAnalyst highlights limited visibility into prescription trends between reporting periods, which can amplify stock volatility and make interim company updates highly influential on share price.
Xeris Pharmaceuticals News
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $3.81 and its highest was $10.08 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $941.47M.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is May 07, 2026 which is in 52 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Mar 02, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.021 by $0.039.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is <0.01.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 172,431,290 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of $0.06 in its last earnings report, beating expectations of $0.021. Following the earnings report the stock price went down -1.634%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (78.57% Upside)
$10.00 (78.57% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 307.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $976.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.73%
12-Months-Change
Fundamentals
Return on Equity
-5.33%
Trailing 12-Months
Asset Growth
19.38%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive tone driven by robust revenue growth (44% FY), first full-year net income, strong adjusted EBITDA ($59.4M), high gross margins (85%+), a strengthened balance sheet and ambitious 2026 guidance (>30% growth midpoint). Management is investing meaningfully in commercial expansion and a high-value pipeline asset (XP-8121) with planned R&D and SG&A step-ups to support future growth. Primary risks highlighted include newly filed Recorlev patent litigation with uncertain timelines, concentration of growth in Recorlev, and near-term increases in R&D and SG&A expenditures that will be absorbed to enable longer-term upside.View all XERS earnings summariesXERS Stock 12 Month Forecast
Average Price Target
$10.00
▲(78.57% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Zymeworks
―
Arcus Biosciences
―
Stoke Therapeutics
―
Rapport Therapeutics, Inc.
―
Ownership Overview
5.65% Insiders
10.91% Mutual Funds
6.10% Other Institutional Investors
64.48% Public Companies and
Individual Investors